The complement component C3 plays a critical role in both TH1 and TH2 responses to antigen - 20/08/11
Boston, Mass
Abstract |
Background |
Complement component C3 is synthesized by keratinocytes and is activated after skin injury. C3 is also synthesized by peritoneal macrophages, which are activated by the adjuvant alum.
Objective |
We sought to investigate the role of C3 in inciting allergic skin Inflammation and systemic immune responses after epicutaneous sensitization or intraperitoneal sensitization with antigen.
Methods |
C3-deficient (C3−/−) mice and wild-type (WT) control animals were subjected to epicutaneous sensitization with the antigen ovalbumin (OVA) on shaved and tape-stripped skin or intraperitoneal immunization with OVA in alum.
Results |
Skin Infiltration by eosinophils and expression of mRNA encoding the TH2 cytokines IL-4 and IL-5 in OVA-sensitized skin sites was impaired in C3−/− mice. Splenocytes from epicutaneously sensitized C3−/− mice secreted less IL-4, IL-5, IL-13, and IFN-γ in response to OVA stimulation than splenocytes from WT control animals. The defect in cytokine secretion by splenocytes was also observed after intraperitoneal immunization of C3−/− mice. C3−/− mice had impaired IgG1, IgG2a, and IgE antibody responses after both epicutaneous and intraperitoneal immunization. The defect in cytokine secretion of C3−/− mice was not due to defective proliferation to antigen, was not observed after anti-CD3 stimulation, and was corrected by the addition of purified C3 protein.
Conclusion |
These results suggest that C3 plays an important role in both the TH1 and TH2 response to antigen in vivo.
Clinical implications |
The complement pathway might be a potential target in the therapy of allergic diseases.
Le texte complet de cet article est disponible en PDF.Key words : Atopic dermatitis, complement, mouse, TH1, TH2
Abbreviations used : APC, SEA, WT
Plan
Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases AR47417 (RSG), AI054471 (HCO), AI039246 (MC), and AI053570 (MC). Disclosure of potential conflict of interest: The authors have declared they have no conflict of interest. |
Vol 117 - N° 6
P. 1455-1461 - juin 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?